Bos Hendrik, Laverman Gozewijn D, Henning Robert H, Tiebosch Anton T M G, de Jong Paul E, de Zeeuw Dick, Navis Gerjan
Department of Nephrology, Groningen University, Groningen, The Netherlands.
J Renin Angiotensin Aldosterone Syst. 2003 Jun;4(2):106-12. doi: 10.3317/jraas.2003.010.
Proteinuria is assumed to play a pathogenetic role in progressive renal damage. Angiotensin-converting enzyme (ACE) inhibition reduces proteinuria and provides renoprotection. This suggests that ACE activity might play a pathogenetic role in the development of proteinuria-induced renal structural damage. We investigated this hypothesis in untreated and treated established adriamycin nephrosis, a model of proteinuria-induced renal damage. In a time-course experiment, the development of renal structural damage in untreated adriamycin nephrotic rats was paralleled by a significant rise in renal ACE activity. Moreover, on cross-sectional analysis, a consistent positive correlation between renal, but not plasma, ACE activity and proteinuria, focal glomerulosclerosis and interstitial injury was present. Notably, these associations were present, not only in the untreated condition, but also during intervention with either ACE inhibition or AT(1)-receptor antagonism. Interestingly, we found that higher renal ACE activity is associated with more severe renal damage for a given amount of proteinuria, suggesting that renal ACE activity may be either a permissive or a promoting factor in the processes by which proteinuria eventually leads to renal structural damage. This relationship was abolished by renin-angiotensin system (RAS)-blockade, suggesting that RAS-mediated effects are involved in the relationship between renal ACE activity and proteinuria-induced renal damage. In conclusion, in untreated as well as treated adriamycin nephrotic rats, renal ACE activity is closely associated with renal outcome. This association appears to be independent of the specific mode of blockade of the RAS. Renal ACE activity is a consistent marker of individual differences in proteinuria-associated renal damage: further studies are needed to investigate a possible pathogenetic role in renal damage.
蛋白尿被认为在进行性肾损伤中发挥致病作用。血管紧张素转换酶(ACE)抑制可减少蛋白尿并提供肾脏保护作用。这表明ACE活性可能在蛋白尿诱导的肾脏结构损伤的发生发展中起致病作用。我们在未经治疗和已治疗的阿霉素肾病(一种蛋白尿诱导的肾损伤模型)中对这一假设进行了研究。在一项时间进程实验中,未经治疗的阿霉素肾病大鼠肾脏结构损伤的发展与肾脏ACE活性的显著升高平行。此外,在横断面分析中,肾脏而非血浆ACE活性与蛋白尿、局灶性肾小球硬化和间质损伤之间存在一致的正相关。值得注意的是,这些关联不仅在未经治疗的情况下存在,而且在ACE抑制或AT(1)受体拮抗剂干预期间也存在。有趣的是,我们发现对于给定的蛋白尿量,较高的肾脏ACE活性与更严重的肾脏损伤相关,这表明肾脏ACE活性可能是蛋白尿最终导致肾脏结构损伤过程中的一个允许或促进因素。肾素-血管紧张素系统(RAS)阻断可消除这种关系,提示RAS介导的效应参与了肾脏ACE活性与蛋白尿诱导的肾脏损伤之间的关系。总之,在未经治疗以及已治疗的阿霉素肾病大鼠中,肾脏ACE活性与肾脏结局密切相关。这种关联似乎独立于RAS阻断的具体方式。肾脏ACE活性是蛋白尿相关肾损伤个体差异的一个一致标志物:需要进一步研究来探讨其在肾损伤中可能的致病作用。